|Bid||49.40 x 2200|
|Ask||65.00 x 900|
|Day's Range||59.20 - 60.50|
|52 Week Range||40.26 - 68.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.00|
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of comScore, ...
FibroGen (FGEN) delivered earnings and revenue surprises of 51.72% and 53.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Francisco-based company said it had a loss of 28 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018. Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Cancer. Conference Call ...
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding FGEN totaled $164 million.
SAN FRANCISCO, Aug. 01, 2018-- FibroGen, Inc., a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday, August 7, 2018, after market close, and ...
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadustat in anemia associated with chronic kidney disease (CKD). The Phase 3 clinical program is evaluating the use of roxadustat for the treatment of anemia in both dialysis-dependent and non-dialysis-dependent CKD patients. “We are pleased to have achieved this critical step in our roxadustat Phase 3 clinical program, and we look forward to reporting topline results from these studies by the end of this year, with pooled safety analyses available in 2019,” said K. Peony Yu, Chief Medical Officer, FibroGen.
SAN FRANCISCO, June 04, 2018-- FibroGen, Inc., a biopharmaceutical company, today announced that management will participate in a Fireside Chat at the Jefferies 2018 Healthcare Conference in New York, ...
FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced Phase 1/2 clinical trial results of pamrevlumab in combination with standard-of-care chemotherapy in patients with locally advanced unresectable pancreatic cancer (LAPC). Principal investigator Vincent J. Picozzi, Jr., M.D., Director, Pancreas Center of Excellence, Virginia Mason Cancer & Digestive Diseases Institutes, presented the results in a discussion poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. “These are some of the most exciting clinical trial results in locally advanced pancreatic cancer I have seen since I began treating pancreatic cancer patients,” said Dr. Picozzi.
I am going to run you through how I calculated the intrinsic value of FibroGen Inc (NASDAQ:FGEN) using the discounted cash flow (DCF) method. Anyone interested in learning a bitRead More...
FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) were presented in several poster presentations at the American Thoracic Society (ATS) 2018 in San Diego, California. Pamrevlumab, a proprietary first-in-class antibody targeting connective tissue growth factor (CTGF) currently being developed for the treatment of fibrotic and fibroproliferative disorders, has demonstrated favorable results in slowing disease progression as measured by forced vital capacity (FVC) in IPF patients in two Phase 2 trials. The poster presentation at ATS presents additional results demonstrating that pamrevlumab treatment achieved a statistically significant reduced rate of progression of lung fibrosis compared to placebo using quantitative high resolution computed tomography (qHRCT).
A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN ) moving towards ...
The San Francisco-based company said it had a loss of 50 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $170 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.
FibroGen generated $69.8 million from investing activities in 2017 compared to $6.6 million in 2016. In 2017, FibroGen generated $496.4 million from financing activities compared to $6.7 million in 2016. This substantial increase was primarily due to the proceeds from a follow-on offering of $471.2 million in April and August 2017 and $34.9 million from the proceeds of an issuance of common stock upon the exercise of stock options and purchases.
Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.
FibroGen (FGEN) generated total revenue of $125.6 million in 2017 compared to $179.5 million in 2016. The company derives its revenue from licenses, milestones, collaboration services, and other revenue. FibroGen’s license and milestone revenues were $96 million in 2017 compared to $137.3 million in 2016.
FibroGen (FGEN) is capitalizing on its extensive experience in fibrosis and hypoxia-inducible factor (or HIF) biology to advance a pipeline targeted for the treatment of anemia, fibrotic disease, cancer, and corneal blindness. Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200. FG-3019 is a fully human monoclonal antibody that inhibits the activity of connective tissue growth factor.